<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article15</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PIONEER_AF-PCI" style="display:block; margin-bottom:10px;">PIONEER AF-PCI Original</a></li>
<h2><strong>PIONEER AF-PCI</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Rivaroxaban with or without Aspirin in Patients with Recent PCI and Atrial Fibrillation".The New England Journal of Medicine. 2016. 375(21):2033-2044.PubMed•Full text•PDFContents<br/>
1Clinical Question<br/>
2Bottom Line<br/>
3Major Points<br/>
4Guidelines<br/>
5Design<br/>
6Population<br/>
6.1Inclusion Criteria<br/>
6.2Exclusion Criteria<br/>
6.3Baseline Characteristics<br/>
6.4Baseline Medications<br/>
7Interventions<br/>
8Outcomes<br/>
8.1Primary Outcomes<br/>
8.2Secondary Outcomes<br/>
9Criticisms<br/>
10Funding<br/>
11Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with nonvalvular atrial fibrillation who have undergone PCI with stent placement, does anticoagulation with rivaroxaban reduce the risk of clinically significant bleeding compared to standard therapy with a vitamin K antagonist plus dual antiplatelet therapy (DAPT)?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
For patients with atrial fibrillation undergoing PCI with stent placement, rivaroxaban in combination with a P2Y12 inhibitor for 12 months, or in combination with very-low-dose rivaroxaban plus DAPT for 1, 6, or 12 months, resulted in a lower rate of clinically significant bleeding compared to standard therapy with a vitamin K antagonist plus DAPT.<br/>
<br/>
<h2><strong>Major Points </strong></h2><br/>
In atrial fibrillation patients who underwent PCI with stenting, treatment with low-dose or very-low-dose rivaroxaban in combination with antiplatelet agents showed a lower risk of bleeding events than traditional therapy with a vitamin K antagonist and DAPT. Efficacy for major cardiovascular events was similar among the groups, although confidence intervals were broad, limiting definite conclusions regarding efficacy.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Currently, no guidelines reflect the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- International, multicenter, randomized, open-label trial<br/>
- N=2,124 patients<br/>
- Group 1 (n=709): Low-dose rivaroxaban (15 mg once daily) plus P2Y12 inhibitor for 12 months<br/>
- Group 2 (n=709): Very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for prespecified duration (1, 6, or 12 months)<br/>
- Group 3 (n=706): Standard therapy with vitamin K antagonist once daily plus DAPT for prespecified duration (1, 6, or 12 months)<br/>
- Enrollment: May 2013 to July 2015<br/>
- Mean follow-up: 12 months<br/>
- Analysis: Modified intention-to-treat<br/>
- Primary outcome: Clinically significant bleeding<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Patients ≥18 years old<br/>
- Paroxysmal, persistent, or permanent nonvalvular atrial fibrillation<br/>
- Underwent PCI with stent placement<br/>
<br/>
Exclusion Criteria<br/>
- Stroke or transient ischemic attack history<br/>
- Significant gastrointestinal bleeding within 12 months<br/>
- Creatinine clearance &lt;30 ml/min<br/>
- Anemia or other conditions increasing bleeding risk<br/>
<br/>
Baseline Characteristics<br/>
- Predominantly white men<br/>
- &lt;10% enrolled in North America<br/>
- Majority intended to use clopidogrel as P2Y12 inhibitor<br/>
<br/>
Baseline Medications <br/>
- Warfarin provided unless contraindicated or part of standard local therapy<br/>
<br/>
<h2><strong>Interventions </strong></h2><br/>
- Rivaroxaban dosing adjusted based on renal function and stratified by intended DAPT duration and P2Y12 inhibitor type <br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- Clinically significant bleeding was lower in groups receiving rivaroxaban than in standard therapy group (16.8% in Group 1, 18.0% in Group 2, 26.7% in Group 3)<br/>
<br/>
Secondary Outcomes<br/>
- Rates of major adverse cardiovascular events were similar across all groups<br/>
- Low stent thrombosis rates with no significant differences among groups<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Not powered to definitively establish superiority or noninferiority for efficacy outcomes<br/>
- Certain rivaroxaban doses not approved for management of acute coronary syndrome or atrial fibrillation<br/>
- Underpowered for individual efficacy end points and subgroups, limiting conclusions on efficacy<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Janssen Scientific Affairs and Bayer Pharmaceuticals<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- "2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes."Journal of the American College of Cardiology.2014;epublished 2014-09-23. Accessed 2014-09-24.<br/>
- "2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines."Circulation.2013;127(4):e362-e425.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
